Imovax Rabies human diploid cell and Isavuconazonium Sulfate

• Generic Name: rabies vaccine, human diploid cell
• Dosage Forms: n.a.
• Other Brand Names: Imovax Rabies

Rabies is a serious disease caused by a virus. Rabies occurs mainly in animals, but a human can get rabies after being bitten by an infected animal. There may be no symptoms at first, but weeks or even months later rabies can cause pain, headaches, tiredness, irritability, fever, hallucinations, seizures, and paralysis. Rabies can be fatal.

You are more likely to be exposed to the rabies virus if you are a veterinarian, animal handler, rabies laboratory worker, or if you come into contact with animals that may carry the virus (including cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats). Traveling to certain countries may also increase your risk of exposure to rabies.

Rabies human diploid cell vaccine is used to protect people who have been bitten by animals (post-exposure) or otherwise may be exposed to the rabies virus (pre-exposure).

This vaccine works by exposing you to a small dose of the virus, which causes the body to develop immunity to the disease. Imovax Rabies is for use in adults and children.

Like any vaccine, the Imovax Rabies may not provide protection from disease in every person.

• Generic Name: isavuconazonium
• Dosage Forms: n.a.
• Other Brand Names: Cresemba

Treatment of invasive aspergillosis; designated an orphan drug by FDA for this indication.

IDSA considers IV voriconazole the drug of choice for primary treatment of invasive aspergillosis; amphotericin B and isavuconazonium recommended as alternatives for primary treatment. For salvage therapy in patients refractory to or intolerant of primary antifungal therapy, IDSA recommends IV amphotericin B, an IV echinocandin (caspofungin, micafungin), oral or IV posaconazole, or itraconazole oral suspension.

Mucormycosis

Treatment of invasive mucormycosis; designated an orphan drug by FDA for this indication.

Esophageal Candidiasis

Treatment of esophageal candidiasis.

Esophageal candidiasis requires treatment with a systemic antifungal (not a topical antifungal).

IDSA recommends oral fluconazole as the preferred drug of choice for treatment of esophageal candidiasis; if oral therapy not tolerated, IV fluconazole or an IV echinocandin (anidulafungin, caspofungin, micafungin) recommended.

For treatment of esophageal candidiasis in HIV-infected adults, CDC, NIH, and IDSA recommend oral or IV fluconazole or itraconazole oral solution. Oral or IV voriconazole, oral isavuconazonium, an IV echinocandin (anidulafungin, caspofungin, micafungin), or IV amphotericin B recommended as alternatives.

Candidemia and Other Invasive Candida Infections

Has been used for treatment of candidemia and other invasive infections caused by Candida; designated an orphan drug by FDA for treatment of invasive candidiasis/candidemia.